Publications

Detailed Information

Oncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cells

DC Field Value Language
dc.contributor.authorRyu, Sun-Hyo-
dc.contributor.authorKim, Ki Hwan-
dc.contributor.authorKim, Hong-Beum-
dc.contributor.authorKim, Mi-Hwa-
dc.contributor.authorKang, Yoonsung-
dc.contributor.authorSeo, Hong Joo-
dc.contributor.authorYou, Ho Jin-
dc.contributor.authorJun, Jae-Yeul-
dc.contributor.authorHyun, Jin Won-
dc.contributor.authorKim, Na-Hee-
dc.date.accessioned2012-06-27T06:59:42Z-
dc.date.available2012-06-27T06:59:42Z-
dc.date.issued2010-09-
dc.identifier.citationCANCER SCIENCE; Vol.101 9; 1990-1996ko_KR
dc.identifier.issn1347-9032-
dc.identifier.urihttps://hdl.handle.net/10371/77619-
dc.description.abstractOncogenic Ras proteins transform cells by way of multiple downstream signaling pathways that promote the genesis of human cancers. However, the exact cellular mechanisms by which downstream targets are regulated are not fully understood. Here, we show that oncogenic Ras reduced Clast1/LR8 transcript levels in mouse NIH3T3 fibroblasts and human WI38 fibroblasts. Clast1/LR8 transcript was undetectable in H460, A549, and H1299 cells showing high Ras activity, but was relatively abundant in DMS53 cells displaying low Ras activity. We also showed that K-Ras siRNA restored Clast1/LR8 expression in H460 and A549 cells, and that inhibitors of DNA methylation and histone deacetylation reversed oncogenic H-Ras-mediated suppression of Clast1/LR8 transcription. Additionally, ectopic expression of Clast1/LR8 inhibited serum-stimulated phosphorylation of ERK1/2 and Akt in H-RasV12-transformed NIH3T3 cells. We further showed that the expression of Clast1/LR8 interfered with oncogenic Ras-induced NIH3T3 cell transformation and invasion. Finally, our results showed that Clast1/LR8 inhibited Ras-induced proliferation of, and tumor formation by, oncogenic H-RasV12-transformed NIH3T3 cells in vivo. This study identifies the downregulation of Clast1/LR8 as a potentially important mechanism by which oncogenic Ras-mediated neoplastic transformation occurs. (Cancer Sci 2010).ko_KR
dc.description.sponsorshipThis research was supported by Chosun University, 2003.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELLko_KR
dc.titleOncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cellsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor류선효-
dc.contributor.AlternativeAuthor김기환-
dc.contributor.AlternativeAuthor김홍범-
dc.contributor.AlternativeAuthor김미화-
dc.contributor.AlternativeAuthor김나희-
dc.contributor.AlternativeAuthor강윤성-
dc.contributor.AlternativeAuthor현진원-
dc.contributor.AlternativeAuthor서홍주-
dc.contributor.AlternativeAuthor전재열-
dc.contributor.AlternativeAuthor유호진-
dc.identifier.doi10.1111/j.1349-7006.2010.01626.x-
dc.citation.journaltitleCANCER SCIENCE-
dc.description.citedreferenceSchubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109-
dc.description.citedreferenceChang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685-
dc.description.citedreferenceMaeda Y, 2006, BRAIN RES, V1104, P18, DOI 10.1016/j.brainres.2006.05.068-
dc.description.citedreferenceBild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296-
dc.description.citedreferenceChang IY, 2005, CANCER RES, V65, P6811-
dc.description.citedreferenceRong R, 2005, ONCOGENE, V24, P4867, DOI 10.1038/sj.onc.1208660-
dc.description.citedreferenceAkino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051-
dc.description.citedreferencePruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200-
dc.description.citedreferenceJiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004-
dc.description.citedreferenceChang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001-
dc.description.citedreferenceOrdway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483-
dc.description.citedreferenceSoejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510-
dc.description.citedreferenceMalumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097-
dc.description.citedreferenceHuang E, 2003, NAT GENET, V34, P226-
dc.description.citedreferenceDownward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969-
dc.description.citedreferenceULKU AS, 2003, CANC TREAT RES, V115, P189-
dc.description.citedreferenceBardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949-
dc.description.citedreferenceDammann R, 2000, NAT GENET, V25, P315-
dc.description.citedreferenceZUBER J, 2000, NAT GENET, V24, P1441-
dc.description.citedreferenceBarradas M, 1999, EMBO J, V18, P6362-
dc.description.citedreferenceContente S, 1999, MOL CELL BIOCHEM, V194, P79-
dc.description.citedreferenceLurton J, 1999, AM J RESP CELL MOL, V20, P327-
dc.description.citedreferenceLorentz O, 1999, ONCOGENE, V18, P87-
dc.description.citedreferenceRosen K, 1998, CURR BIOL, V8, P1331-
dc.description.citedreferenceCampbell SL, 1998, ONCOGENE, V17, P1395-
dc.description.citedreferenceRodriguezViciana P, 1997, CELL, V89, P457-
dc.description.citedreferenceWHITE MA, 1995, CELL, V80, P533-
dc.description.citedreferenceCOWLEY S, 1994, CELL, V77, P841-
dc.description.citedreferenceLOWY DR, 1993, ANNU REV BIOCHEM, V62, P851-
dc.description.citedreferenceBOS JL, 1989, CANCER RES, V49, P4682-
dc.description.citedreferenceYOU M, 1989, P NATL ACAD SCI USA, V86, P3070-
dc.description.citedreferenceRODENHUIS S, 1988, CANCER RES, V48, P5738-
dc.description.citedreferenceBRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share